Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Retained Earnings: 2012-2017

Historic Retained Earnings for Ascendis Pharma A (ASND) over the last 3 years, with Sep 2017 value amounting to $23.5 million.

  • Ascendis Pharma A's Retained Earnings rose 88.25% to $23.5 million in Q3 2017 from the same period last year, while for Sep 2017 it was $23.5 million, marking a year-over-year increase of 88.25%. This contributed to the annual value of $14.4 million for FY2016, which is 126.99% up from last year.
  • As of Q3 2017, Ascendis Pharma A's Retained Earnings stood at $23.5 million, which was up 18.16% from $19.9 million recorded in Q2 2017.
  • Over the past 5 years, Ascendis Pharma A's Retained Earnings peaked at $23.5 million during Q3 2017, and registered a low of $3.7 million during Q4 2013.
  • Moreover, its 3-year median value for Retained Earnings was $10.8 million (2016), whereas its average is $11.7 million.
  • Data for Ascendis Pharma A's Retained Earnings shows a peak YoY surged of 124.35% (in 2016) over the last 5 years.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Retained Earnings stood at $3.7 million in 2013, then soared by 34.79% to $5.0 million in 2014, then climbed by 25.29% to $6.3 million in 2015, then spiked by 124.35% to $14.0 million in 2016, then surged by 88.25% to $23.5 million in 2017.
  • Its last three reported values are $23.5 million in Q3 2017, $19.9 million for Q2 2017, and $16.7 million during Q1 2017.